Atea Pharmaceuticals Inc (AVIR NASDAQ) stock market data APIs
$3.1
-0.06(-1.9%)
as of January 24, 2025
Atea Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Prev. Close
3.16
Open
3.1
Volume
345 K
High
3.22
Low
3.06
52 wk Range
2.75-4.6
Market Cap
262 M
Shares Outstanding
84 463 K
Revenue
192 M
EPS
-0.37
Beta
0.17
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Atea Pharmaceuticals Inc data using free add-ons & libraries
Get Atea Pharmaceuticals Inc Fundamental Data
Atea Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 192 M
- EBITDA: -124 883 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: -0.49
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Atea Pharmaceuticals Inc News
New
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
Atea Pharmaceuticals, Inc. AVIR, a clinical-stage company, reported positive initial data from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir and ruza...
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
Atea Pharmaceuticals, Inc. A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study Phase 3 SUNRISE-3 Enrol...
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, Inc. BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and de...
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
Atea Pharmaceuticals, Inc. First Clinical Data for Coadministration of Bemnifosbuvir and Ruzasvir Show Combination Was Well Tolerated in a Phase 1 Study Plasma Pharmacokinetic (PK) Profiles of Bemni...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
